NASDAQ:ASMB
Assembly Biosciences Stock Signals
Latest Data & Signals Issued
| Signal Type | Signal Value | Data | |
|---|---|---|---|
| Score | -6.765 | 26 days ( 32.03 % ) | |
| Last Price | $1.04 | -2.80 % | |
| High/ Low | $1.01 - $1.06 | -13.86% | |
| Chg 7 Days | -15.45 % | $1.23 $1.04 | |
| Chg 30 Days | -26.24 % | $1.41 $1.04 | |
| Chg 12 mos | -50.71 % | $2.11 $1.04 | |
| Trend - 3 mos | -14.02 % | Width: 64.32 % | |
| Trend - 12 mos | -32.46 % | Width: 188.72 % | |
| Pred. range - 3 mos | $0.83 - $1.36 | -20.45 % - 30.71 % | |
| Pred. range - 12 mos | $0.413 - $1.19 | -60.33 % - 14.53 % | |
| Short mv avg 3 mos | Buy | 2023-03-14 - 9 days | |
| Long mv avg 3 mos | Sell | 2023-02-15 - 27 days | |
| Short/Long mv avg 3 mos | Sell | 2023-02-16 - 26 days | |
| Short mv avg 12 mos | Buy | 2023-03-07 - 14 days | |
| Long mv avg 12 mos | Sell | 2023-02-17 - 25 days | |
| Short/Long mv avg 12 mos | Sell | 2023-02-27 - 20 days | |
| Pivot Short | Sell | 2023-01-31 - 38 days | |
| Bollinger | Buy | 2022-12-07 - 74 days | |
| MACD | Sell | No Dates Stored For This Signal |
ASMB splits
| Date | Ratio | Status |
|---|---|---|
| 2014-07-14 | 1:5 |
About Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical tri... ASMB Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
